PETRA: First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations Meeting Abstract


Authors: Yap, T. A.; Im, S. A.; Schram, A. M.; Sharp, A.; Balmana, J.; Baird, R. D.; Brown, J. S.; Schwaederle, M.; Pilling, E. A.; Moorthy, G.; Linardopoulos, S.; Dowson, A.; Pound, C.; Lukacs, E.; Cosulich, S.; Luen, S. J.
Abstract Title: PETRA: First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations
Meeting Title: 113th Annual Meeting of the American Association for Cancer Research (AACR)
Journal Title: Cancer Research
Volume: 82
Issue: 12 Suppl.
Meeting Dates: 2022 Apr 8-13
Meeting Location: New Orleans, LA
ISSN: 0008-5472
Publisher: American Association for Cancer Research  
Date Published: 2022-06-15
Language: English
ACCESSION: WOS:000892509500159
PROVIDER: wos
DOI: 10.1158/1538-7445.AM2022-CT007
Notes: Meeting Abstract: CT007 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Alison Michele Schram
    123 Schram